New insights into irritable bowel syndrome: from pathophysiology to treatment

This item is provided by the institution :
Hellenic Society of Gastroenterology   

Repository :
Annals of Gastroenterology   

see the original item page
in the repository's web site and access all digital files if the item*



New insights into irritable bowel syndrome: from pathophysiology to treatment (EN)

Hadjivasilis, Alexandros
Michalinos, Adamantios
Agouridis, Aris P.
Tsioutis, Constantinos
Christodoulou, Dimitrios K.
Ntourakis, Dimitrios

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

2019-11-13


Irritable bowel syndrome (IBS) is the most common reason to visit a gastroenterologist. IBS was believed to be a functional disease, but many possible pathophysiologic mechanisms can now explain the symptoms. IBS patients are classified into subtypes according to their predominant bowel habit, based on the Rome IV criteria. These include diarrhea-predominant and constipation-predominant IBS, as well as the mixed type, a combination of the two. Usually, IBS treatment is based on the predominant symptoms, with many options for each subtype. A new promising treatment option, fecal microbiota transplantation, seems to have beneficial effects on IBS. However, treating the pathophysiological causative agent responsible for the symptoms is anemerging approach. Therefore, before the appropriate therapeutic option is chosen for treating IBS, a clinical evaluation of its pathophysiology should be performed. Keywords Irritable bowel syndrome, pathophysiology, Rome IV criteria, treatment, fecal microbiota transplantation Ann Gastroenterol 2019; 32 (6): 554-564 (EN)


English

Hellenic Society of Gastroenterology (EN)


1792-7463
1108-7471
Annals of Gastroenterology; Volume 32, No 6 (2019); 554 (EN)

Copyright (c) 2019 Annals of Gastroenterology (EN)




*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)